Search Medical Condition
Please enter condition
Please choose location from dropdown

Gerlingen, Germany Clinical Trials

A listing of Gerlingen, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (153) clinical trials

German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm)

To register a large number of patients with the diagnosis of a BCR-ABL 1- negative myeloid neoplasm (according to WHO 2008 classification) in participating centers To store samples from all patients (e.g. bone marrow aspirate, peripheral blood, plasma, and buccal swap, skin biopsy samples in exceptional cases) To perform morphologic ...

Phase N/A

4.63 miles

Learn More »

Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Evaluation of remission status will take place 4 months after treatment. In addition, it will be tested whether patients with non-optimal response will have a benefit from a second cycle of cladribine. Non-optimal response is: patients with detectable residual disease; achievement of partial remission or detectable residual infiltration in the ...

Phase

4.63 miles

Learn More »

Registry Study on Patient Characteristics Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project

This is a registry study in adult patients with newly diagnosed or refractory/relapsed myeloid neoplasms Investigator's sites: 60-70 sites in Germany and Austria Estimated duration of observation of an individual patient: 10 years maximum Objectives To register all patients with acute myeloid leukemia and related precursor neoplasms, acute leukemia of ...

Phase N/A

4.63 miles

Learn More »

International HIT-MED Registry (I-HIT-MED)

The following patients can be included in this registry: Children and adults with Medulloblastoma (MB) Ependymoma CNS-primitive neuroectodermal tumours (CNS-PNET) including CNS neuroblastoma, CNS ganglioneuroblastoma, Medulloepithelioma, Ependymoblastoma, CNS-PNET not otherwise specified (NOS) Pineoblastoma Pineal parenchymal tumour of intermediate differentiation Papillary tumour of the pineal region Who are not included in ...

Phase N/A

4.63 miles

Learn More »

Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

OBJECTIVES: Primary - Compare the event-free survival of pediatric patients with high-risk neuroblastoma treated with standard induction chemotherapy vs topotecan hydrochloride-containing induction chemotherapy followed by myeloablative autologous stem cell transplantation and consolidation therapy with isotretinoin. Secondary - Compare the overall survival of patients treated with these regimens. - Compare early ...

Phase N/A

4.63 miles

Learn More »

Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years

The DSMM V protocol is to compare a consolidation treatment for standard-risk patients not displaying del(13) at initial diagnosis following two cycles of high-dose melphalan 200 mg/m² each supported by autologous stem cell retransfusion with interferon versus PEG-interferon. Patients with del(13) are screened for availability of a fully HLA-matched related ...

Phase

4.63 miles

Learn More »

Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma

In this study for elderly myeloma patients lenalidomide plus low-dose dexamethasone until progression is being compared with age-adjusted tandem high-dose melphalan 140 mg/m augmented by induction with 3 cycles of lenalidomide plus low-dose dexamethasone before transplantation and lenalidomide maintenance after transplantation.

Phase

4.63 miles

Learn More »

Therapy Management With Nab-Paclitaxel in Daily Routine

Despite treatment improvements in breast cancer, a large number of patients still progress to the metastatic stage. Metastatic breast cancer patients have an extremely unfavorable prognosis. Not only efficacy, but also quality of life are in the focus when planning a therapy or therapy sequence for metastatic breast cancer patients. ...

Phase N/A

4.63 miles

Learn More »

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

The aim of the LR-treatment arm is to confirm the high rate of event-free survival in patients between the ages of 3 to 5 years and less than 22, with 'standard risk' medulloblastoma with a low-risk biological profile. Patients eligible for the study will be those with non-metastatic medulloblastoma (by ...

Phase

4.63 miles

Learn More »

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

Study Duration and Schedule: The duration of the trial for each subject is expected to be 24 months. The duration for each individual patient includes about 6 months first-line therapy according to treating physicians choice with HLA ligandome analyses of CLL cells and selection of patient-individual multipeptide vaccine being performed ...

Phase

4.63 miles

Learn More »